The First Patient Has Been Dosed in a Trial for Glioblastoma, Medulloblastoma, and Ependymoma
source: pixabay.com

The First Patient Has Been Dosed in a Trial for Glioblastoma, Medulloblastoma, and Ependymoma

Mustang Bio, a biopharmaceutical company, and City of Hope, a cancer center, have just revealed that their first participant in their Phase 1 clinical trial for leptomeningeal brain tumors including…

Continue Reading The First Patient Has Been Dosed in a Trial for Glioblastoma, Medulloblastoma, and Ependymoma
FDA Grants Rare Pediatric Disease Designation for WP1066
GDJ / Pixabay

FDA Grants Rare Pediatric Disease Designation for WP1066

The FDA has recently granted its Rare Pediatric Disease designation to Moleculin's WP1066 for three indications: atypical teratoid rhabdoid tumor, diffuse intrinsic pontine glioma, and medulloblastoma. This designation will aid…

Continue Reading FDA Grants Rare Pediatric Disease Designation for WP1066

Researchers at UNC Are Experimenting With a New Way to Deliver Drugs For Medulloblastoma

A team of researchers from the University of North Carolina have been exploring an experimental method of delivering drugs to medulloblastoma that involves converting skin cells into stem cells that…

Continue Reading Researchers at UNC Are Experimenting With a New Way to Deliver Drugs For Medulloblastoma